Testosterone in Men Requires a Clinical Approach, Not a Transactional One

By Jill | Precision Health

A man comes in and tells me he started testosterone on his own. A friend gave him a referral, or he found a clinic online that prescribed it after a quick telehealth visit. He felt great for a few months. Then the fatigue came back. His mood got worse. He’s retaining water. He’s irritable in a way he wasn’t before. He has no idea why, because nobody’s been checking anything.

This is one of the most common stories I hear from men who come to Precision Health after starting testosterone somewhere else. And it points to something the testosterone conversation rarely addresses: starting TRT isn’t the hard part. Managing it is.

The Gap: Most Testosterone “Programs” Are Just Prescriptions

The demand for testosterone therapy has tripled over the past two decades. By 2013, more than 2.3 million American men were already on it — and that number has continued to climb (Basheer et al., International Brazilian Journal of Urology, January 2025). As the market expanded, so did the shortcuts.

The standard model at many clinics and online platforms: confirm your testosterone is low, prescribe, and follow up … eventually. Or not at all. What’s missing from that model is exactly what makes the difference between testosterone therapy that genuinely optimizes your health and testosterone therapy that creates a new set of problems.

Testosterone doesn’t just raise one number. It moves a whole system. And a system that’s moving needs to be watched.

What Actually Happens When You Start Testosterone

Here’s the biology that most one-size-fits-all prescribers skip over.

Testosterone converts to estrogen. Your body uses an enzyme called aromatase to convert a portion of testosterone into estradiol — a form of estrogen. Some conversion is normal and healthy; estrogen protects bone density and cardiovascular function in men. Too much, and you get symptoms like water retention, mood swings, reduced libido, and breast tissue sensitivity. Too little — often caused by aggressive use of aromatase inhibitors without proper monitoring — causes joint pain, low libido, and bone loss. The balance matters, and the balance is individual.

Testosterone raises your red blood cell count. This is called erythrocytosis, and it’s the most common adverse effect of testosterone therapy (Walia, Trends in Urology & Men’s Health, December 2025). Testosterone signals your body to produce more red blood cells, which thickens the blood. A modest increase is harmless. But when hematocrit — the percentage of your blood that’s red blood cells — climbs above certain thresholds, the risk of clotting events goes up meaningfully. Current guidelines set 50% as a relative contraindication to starting therapy and 54% as a threshold requiring dose reduction or temporary discontinuation.

Your body’s own production shuts down. Exogenous testosterone suppresses the hormonal signal that tells your testes to produce testosterone on their own. For men not concerned with fertility, this is manageable. For men who are, it’s a critical consideration that requires a different clinical approach from the start — not as an afterthought.

What the Research Actually Showed

For years, testosterone therapy carried a black box warning about cardiovascular risk — a warning that quietly kept many men who genuinely needed it from pursuing treatment. The 2023 TRAVERSE trial changed that conversation permanently.

TRAVERSE enrolled 5,246 men with confirmed hypogonadism and elevated cardiovascular risk — the population most likely to be harmed if the concern was real. The result: major adverse cardiovascular events occurred in 7.0% of men on testosterone versus 7.3% on placebo. Non-inferior. No increased cardiovascular risk (Lincoff, Bhasin et al., New England Journal of Medicine, 2023).

In February 2025, the FDA acted on that data: it removed the cardiovascular black box warning from testosterone labeling class-wide (FDA Drug Safety Communication, February 2025). This is a meaningful shift. It means the longstanding hesitation around testosterone in men with cardiovascular history is no longer supported by the best available evidence — when therapy is appropriately managed. That last phrase carries all the weight.

What “Appropriately Managed” Actually Means

This is where most programs fall short, and where the clinical detail matters.

Baseline matters. Before starting testosterone, a thorough workup should include total and free testosterone (collected in the morning when levels are highest), hematocrit, PSA, comprehensive metabolic panel, and estradiol. You can’t navigate a system you haven’t mapped.

The first 90 days are the most important. After initiating therapy, labs should be rechecked at 3 months — specifically testosterone levels and hematocrit. This is the window where most problems first appear and are easiest to correct: a dose adjustment, a formulation change, an intervention before a small imbalance becomes a real one.

Monitoring doesn’t end after the first year. Once stable, most patients need labs every six months. Hematocrit should be evaluated at 3 months, 6 months, and annually thereafter. Estradiol gets checked when symptoms suggest it — mood changes, water retention, libido shifts. PSA is part of ongoing prostate safety monitoring. None of this is optional — it’s the protocol that makes the therapy safe (Walia, Trends in Urology & Men’s Health, December 2025; Basheer et al., International Brazilian Journal of Urology, January 2025).

Formulation affects risk. Not all delivery methods create the same hematocrit response. Injectable testosterone tends to produce larger swings in red blood cell production; topical and subcutaneous options often result in more stable levels. Choosing the right formulation for your physiology isn’t a preference question — it’s a clinical one.

Why This Is Different From “Just Taking Testosterone”

There’s a version of testosterone therapy that’s transactional: you have low T, you get a prescription, you refill it when it runs out. There’s another version that’s clinical: your levels are measured, your response is tracked, your dosing is adjusted as your physiology changes, and the variables that affect your safety are watched over time.

The first version is available on a lot of platforms right now. The second version is what actually optimizes your healthspan.

The difference shows up over time. The man who’s just taking testosterone might feel better initially — and then hit a wall as estrogen creeps up, or as hematocrit climbs, or as he realizes his dose has never been adjusted despite the fact that his physiology has changed. The man in a managed program sees those shifts before they become problems and has a clinical partner who can respond.

What We Do Differently at Precision Health

When a man starts a testosterone optimization program at Precision Health, he’s not getting a prescription — he’s getting a protocol. That means a full baseline workup, a treatment plan built around his individual physiology and goals, labs at 3 months, and an ongoing monitoring schedule that tracks the variables that matter: testosterone, estradiol, hematocrit, PSA, and any symptom shifts that suggest something needs adjusting.

We also have the conversation up front that a lot of clinics avoid: what are your fertility goals? What’s your cardiovascular history? What formulation fits your life, not just your lab values? These aren’t administrative questions — they’re the questions that determine whether this goes well over years, not just months.

The Bigger Picture: Testosterone as Part of Longevity Strategy

Optimized testosterone isn’t just about energy and libido, though those matter. It’s connected to muscle preservation, bone density, metabolic function, and cognitive health — all of which are central to what we mean by healthspan. A 2024 substudy from TRAVERSE found that testosterone reduced progression from prediabetes to type 2 diabetes in hypogonadal men (Bhasin et al., JAMA Internal Medicine, April 2024). Separate TRAVERSE data showed significant reduction in fracture risk in men with low testosterone (Snyder et al., New England Journal of Medicine, January 2024).

These are not minor quality-of-life adjustments. These are outcomes that shape the next decade of your health. But they only happen in a program that’s calibrated and maintained — not just started.

The Bottom Line

Testosterone therapy, done well, is one of the most evidence-supported tools in longevity medicine for men. Done carelessly, it’s a system pushed out of balance with nobody watching. The research has cleared the cardiovascular concern that held the field back for years. What it hasn’t changed is this: the outcomes depend on the management, not just the molecule.

If you’re already on testosterone and haven’t had labs in more than six months, that’s worth addressing. If you’re considering it and want a program built around your specific physiology — not a generic protocol — that’s exactly what we do.

Ready to do this right? Schedule a consultation and let’s build a plan that actually works long-term.

Sources

Lincoff AM, Bhasin S, Flevaris P, et al. “Cardiovascular safety of testosterone-replacement therapy.” New England Journal of Medicine, 2023;389(2):107–117.

FDA. “FDA issues class-wide labeling changes for testosterone products.” Drug Safety Communication. February 28, 2025.

Walia R. “Testosterone replacement, where are we in 2025?” Trends in Urology & Men’s Health, December 2025.

Basheer B, Ila V, Barros R, et al. “Management of adverse effects in testosterone replacement therapy.” International Brazilian Journal of Urology, January 2025.

Bhasin S, Lincoff AM, Nissen SE, et al. “Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial.” JAMA Internal Medicine, April 2024;184(4):353–362.

Snyder PJ, Bauer DC, Ellenberg SS, et al. “Testosterone treatment and fractures in men with hypogonadism.” New England Journal of Medicine, January 2024;390(3):203–211.